212 related articles for article (PubMed ID: 20831551)
1. High-dose loading with extended release quetiapine.
Chae BJ
J Clin Pharm Ther; 2010 Aug; 35(4):487-9. PubMed ID: 20831551
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.
Bortnick B; El-Khalili N; Banov M; Adson D; Datto C; Raines S; Earley W; Eriksson H
J Affect Disord; 2011 Jan; 128(1-2):83-94. PubMed ID: 20691481
[TBL] [Abstract][Full Text] [Related]
3. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
[TBL] [Abstract][Full Text] [Related]
4. [Administration of once-daily extended release quetiapine in schizophrenic disorders].
Bartkó G
Neuropsychopharmacol Hung; 2007 Dec; 9(4):189-95. PubMed ID: 18510263
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia.
Möller HJ; Johnson S; Mateva T; Brecher M; Svensson O; Miller F; Meulien D;
Int Clin Psychopharmacol; 2008 Mar; 23(2):95-105. PubMed ID: 18301124
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
Meulien D; Huizar K; Brecher M
Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
[TBL] [Abstract][Full Text] [Related]
8. Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia.
Lee JG; Lee JI; Kim YT; Kim CE; Kim CY; Yoon JS; Yoo SY; Kim YH
Hum Psychopharmacol; 2012 Jul; 27(4):403-10. PubMed ID: 22753400
[TBL] [Abstract][Full Text] [Related]
9. Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series.
Pajonk FG; Schwertner AK; Seelig MA
J Psychopharmacol; 2006 Jan; 20(1):119-24. PubMed ID: 16204326
[TBL] [Abstract][Full Text] [Related]
10. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
Riesenberg RA; Baldytcheva I; Datto C
Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
De Deyn PP; Eriksson H; Svensson H;
Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537
[TBL] [Abstract][Full Text] [Related]
12. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study.
Peuskens J; Trivedi JK; Brecher M; Miller F;
Int Clin Psychopharmacol; 2010 May; 25(3):183-7. PubMed ID: 20216222
[TBL] [Abstract][Full Text] [Related]
13. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
Kasper S; Montagnani G; Trespi G; Di Fiorino M
Int Clin Psychopharmacol; 2015 Jan; 30(1):14-22. PubMed ID: 25356632
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine extended release: in schizophrenia.
Baldwin CM; Scott LJ
CNS Drugs; 2009; 23(3):261-9. PubMed ID: 19320534
[TBL] [Abstract][Full Text] [Related]
15. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.
Datto C; Berggren L; Patel JB; Eriksson H
Clin Ther; 2009 Mar; 31(3):492-502. PubMed ID: 19393840
[TBL] [Abstract][Full Text] [Related]
16. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.
Sheehan DV; Locklear J; Svedsäter H; Datto C
Int Clin Psychopharmacol; 2012 Sep; 27(5):239-48. PubMed ID: 22859063
[TBL] [Abstract][Full Text] [Related]
17. Quetiapine: efficacy, tolerability and safety in schizophrenia.
Miodownik C; Lerner V
Expert Rev Neurother; 2006 Jul; 6(7):983-92. PubMed ID: 16831113
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine XR: current status for the treatment of major depressive disorder.
Pae CU; Sohi MS; Seo HJ; Serretti A; Patkar AA; Steffens DC; Masand PS
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1165-73. PubMed ID: 20307622
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and tolerability of quetiapine in hospitalised schizophrenic patients during the acute treatment phase: a PMS study].
Leweke FM; Gerth CW; Koethe D; Nolden BM; Klosterkötter J
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):211-9. PubMed ID: 17230308
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
